Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Feb 12, 2018 in Benign prostatic hyperplasia | 0 comments

In a nutshell

This study aimed to assess the effectiveness of silodosin (Rapaflo) to treat patients with urinary symptoms due to benign prostatic hyperplasia (BPH – an enlarged prostate). The study found that silodosin improved urinary symptoms and quality of life in patients with BPH who did not respond to tamsulosin (Cialis).

Some background

Tamsulosin is a common drug used to treat BPH. It works on receptors in the bladder that help relax bladder muscles. However, some patients may not respond to this drug or experience side effects. Whether switching to silidosin (a similar drug) is effective in these patients has not been fully studied.

Methods & findings

96 patients were included in the study. Patients with BPH were taking tamsulosin 0.4 mg once daily for 12 months and not responding to therapy. All patients were switched to silodosin 8 mg once daily.

After 8 weeks, average prostate symptoms were reduced and bladder symptoms improved. In total, 18 patients (18.5%) achieved a clinically meaningful reduction in prostate symptoms.

Quality of life also improved from the beginning to 8 weeks. Side effects were found in 19.7% of patients and included problems with ejaculation (in 15.9% of patients).

 

The bottom line

The study concluded that silodosin was an effective treatment for BPH in patients not responding to tamsulosin.

The fine print

The dose of silodosin was higher than the dose of tamsulosin in the study. This can affect treatment response.

Published By :

European review for medical and pharmacological sciences

Date :

Nov 01, 2017

Original Title :

Role of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study.

click here to get personalized updates